Mon, Dec 22, 2014, 5:27 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

mgm2020 573 posts  |  Last Activity: 1 hour 59 minutes ago Member since: Mar 3, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mgm2020 mgm2020 1 hour 59 minutes ago Flag

    $40 from $26. Their stock analyst is rated #9 out of over 3000 analysts.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 2 hours 29 minutes ago Flag

    Your key word is "today's" leading antisense technology. That technology, while it has shown success, has also been plagued by toxicity and tolerance issues. IDRA knew what they were doing when they licensed the 2nd gen. science to ISIS. Now it is ALL available to IDRA, and I believe IDRA holds hundreds of patents on the 3rd gen science.

    Sentiment: Strong Buy

  • Reply to

    Why the drop today ?

    by brettgravatt 6 hours ago

    Gilead started this whole thing which has been going on for at least 6 months by pricing their drug in the US at $100,000 for ONE treatment. In Egypt it costs $900! And there is a wide discrepancy on pricing in other countries. ACAD will have NO issues, and they have said that they will be comparable to other anti-psychotic meds as far as pricing. My guess is that there will be a slight premium on pricing since it is in a class completely by itself, and it will be the drug of choice for every physician/neurologist/psychiatrist treating patients with PDP.

    Sentiment: Strong Buy

  • I believe the Baker Brothers had the same feeling, which is why they convinced Agrawal to step aside as CEO and tapped their long-time friend and colleague who has been down this exact same road before---and VERY SUCCESSFULLY---to take over the helm and properly steer the company. He will be able to determine which direction will deliver the highest combination of positive outcome, company expense, and risk/reward. And we should be getting a few announcements in January. Any announcement will likely advance the stock considerably as it will reduce the amount of uncertainty. And, since the WM is open label there may also be some kind of announcement or indication of the progress of those trials.

    Sentiment: Strong Buy

  • in this country, but in Egypt it only cost 900 dollars! As soon as they announced their pricing structure it began to provoke controversy. The fact that their stock is only down 10% or so indicates that the market thinks this will not have a lasting or financially more damaging effect on the company and GILD will resolve the issue----which they will. This is no way has any effect on IDRA, their progress, or their value as a company and future drug franchise. $4 is the magic number. Buy here while you can---it's not going to last.

    Sentiment: Strong Buy

  • outsmart the market, the stock, and the biggest insider of them all when the NASDAQ has been red hot since the market realized that the low price of oil IS a benefit to everyone, the stock has lifted dramatically on GREAT NEWS with more coming and is poised to surge higher just like 1 year ago(and STAY THERE this time), AND the CEO---the biggest insider of them all---bought 200,000 shares as quickly as he could after taking the position! Those are 3 considerable forces to try to fight. IF the stock drops, and you can----add on the dips. They will not last. Heading into next year with some exciting news expected in January, there will be no extended dips or anything other than a few shallow ones giving you the chance to pick up shares while the price is still near what Milano paid. It won't stay here for much longer.

    Sentiment: Strong Buy

  • K---here is a copy of a previous post explaining the links between ISIS and IDRA from 2006. Maybe this will help:
    "followthebakerbros • Dec 13, 2014 6:49 PM Flag
    Here is a 2006 story for background that tells you how ISIS bought 2nd generation antisense from Idera in 2001:
    With so many companies working on multiple approaches to interrupting messenger RNA and, hence, protein production, it comes as no surprise that the intellectual property (IP) surrounding antisense is a tangled web of cross-licensing agreements.
    As the owner of patents describing the mechanism of action for antisense, Isis Pharmaceuticals has a finger in almost every pie. The company has more than 1,500 patents covering most angles of antisense technology. "Part of our strategy is to own as much of the patent real estate as possible," says Frank Bennett, senior vice president of research at Isis.
    While much of that IP came from internal discovery, Isis bolstered its position in 2001 through a cross-licensing agreement with Hybridon, now called Idera Pharmaceuticals. Isis paid $34.5 million for access to Hybridon's antisense patent portfolio, while allowing Hybridon the freedom to work under Isis' suite of patents. Both companies retained the right to sublicense their respective portfolios to third parties.
    Though Idera has shifted its development efforts away from first- and second-generation antisense to focus on RNA interference (RNAi)-based therapeutics, the company continues to have a stake in the broader antisense arena. Idera has more than 500 patents, including IP that covers second-generation chemistry, oral delivery of oligonucleotide-based drugs, and some 25 gene targets related to cancer, viral infections, or angiogenesis, says Sudhir Agrawal, Idera's chief executive officer and chief scientific officer. "Whoever is using second-generation technology is working under a license from Idera," he notes.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Dec 19, 2014 10:07 PM Flag

    You have contradicted yourself a few times in your posts. You said you were in "in the $1's" but you also said that you just initiated a small position in another post. You said you would add more in the $3's, but you just had your best chance to add when the stock dropped from $4.45 down to $3.50(before the market got wind of Milano's purchase)and apparently didn't. The stock IS in a completely different position now then it was 1 year ago, and when the stock pulled back a year ago it had also begun it's run from a much lower price base. If you are given the opportunity at all to purchase in the $3's, it will be a very brief and very shallow dip. With the CEO purchasing at $4 and stock-moving news expected in the beginning of January you better act fast. But, my question to you is, if you really DID own in the $1's---WHY did you sell, or not add at a lower price on the way up. You have to be kicking yourself for getting out and having to rebuy at triple the price. I hope we all make a lot of money on IDRA but at this stage things will start popping fast, and if you think that the stock will get back to the mid to low $3's I think you're nuts-----and you may have to adjust that target soon to getting back to the mid to low $4's once it's above $5.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Dec 19, 2014 6:15 PM Flag

    Yes---but nothing was announced regarding IDRA and any indexes.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Dec 19, 2014 5:59 PM Flag

    Just like Cramer. The market goes down for 2 days and you better shift all of your money into safer dividend stocks. Then it zooms back up 2 days later and it's "you got to go with the momentum and biotech stocks". It makes me sick the way they change their minds everyday.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Dec 19, 2014 5:53 PM Flag

    Skiing should be awesome out there right now. One storm after another. I'd rather be in Florida.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Dec 19, 2014 5:45 PM Flag

    OK---so tell me what you think the significance of a 600,000 share buy means as far as rebalancing goes? If IDRA was added to a few index funds then that is definitely a positive.

    Sentiment: Strong Buy

  • 600,000 shares bought just before the close buying up the share price. Here are a few theories:
    1) A fund was making a large purchase to either establish a position or begin a position
    2) Another insider was buying a large block of stock or a few insiders were buying
    3) A brokerage firm notified it's best clients that it was going to come out with a recommendation on Monday and alerted those clients to buy as part of their "service"
    4) A large short position was closed by either a fund or individual that realized it was the wrong position to be in and the wrong time for it
    The bottom line, though, no matter what the situation was behind the large purchase is that it, for some reason, HAD TO be made TODAY. There was no waiting until next week--no waiting for the price to come down a few more pennies---There was a REASON WHY this enormous block trade had to be made TODAY. And no matter exactly what the reason was for the purchase, it has to be seen as another positive for the stock. Not just Monday, but the remainder of the year and the beginning of 2015 will be very interesting and exciting for all of us here. There could be a major catapult higher coming up, and, if someone can purchase a half a million shares and not give a hoot that the price is above $4(which is still ridiculously low) then it's really silly and potentially self-destructive to feel that you have to wait for a few less pennies to buy.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Dec 19, 2014 3:24 PM Flag

    Yep. You'll be much richer than me because you bought at $3.98 and I bought at $4.02. REALLY?

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Dec 19, 2014 3:17 PM Flag

    Just bumped my bid up to $4.02-----come to papa.

    Sentiment: Strong Buy

  • I have no problem adding here, and am very excited about the end of 2014 and next year.

    Sentiment: Strong Buy

  • Reply to

    Eduardo , MGM, Stock2013 & Other IDERA LONG’s

    by amano_7 Dec 19, 2014 2:28 PM
    mgm2020 mgm2020 Dec 19, 2014 2:38 PM Flag

    Thank you amano, and you too. I have been in many biotechs, but IDRA is the first one I have been in that has a combination of low price, reasonable share float, a considerable pipeline with many directions and conditions the company can pursue, a world-class scientist leading the discovery and development process, significant positive data that has been presented at top-tier medical conferences, and now a CEO with the pedigree and exact type of experience you want and need to lead a company like this into the future. That is why this is such a special opportunity, and much more of a true investment than a tradable biotech. This is one to potentially retire on, and it will definitely be a very interesting ride.

    Sentiment: Strong Buy

  • Reply to

    We've seen this before...

    by kgtradesabit Dec 19, 2014 2:20 PM
    mgm2020 mgm2020 Dec 19, 2014 2:26 PM Flag

    I think that you need to buy the rallies also. And right now the market is in rally mode. And IDRA's January history indicates you want to own this stock going in to January.

    Sentiment: Strong Buy

  • What a bunch of "little brains" with a long -term horizon of 5 minutes. There were plenty of people shouting "it's dropping back under $10" with ISIS 2 years ago----and they were right! It did drop under $10, and it's now $64!! So----did it matter if you bought at $9.75 or $12, or $14?? The key is to be IN the stock when it rises, and since no one can see the future that means you must OWN the stock. But you know who can come the closest to seeing the future with IDRA? The new CEO Vin Milano. And what did he just do? That's right---he BOUGHT 200,000 shares at $4. I think I will trust his vision, just like the Viropharma investors did when he took that stock from $9 to $50 in just 6 years.

    Sentiment: Strong Buy

  • Reply to

    Temporary infestation of 'shorts'?

    by prs_hope Dec 19, 2014 1:51 PM
    mgm2020 mgm2020 Dec 19, 2014 2:00 PM Flag

    This is nothing. Wait until the stock goes on a tear and hits a new 52 week high early next year. The board will be full of bashers, shorts, knuckleheads, etc.... When all they really need to do is JUST GO LONG! Why can't they just use their energy for good instead of evil?

    Sentiment: Strong Buy

KERX
14.70-0.09(-0.61%)Dec 22 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.